{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:29:50Z","timestamp":1786609790929,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Manatu Hauora | Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["16-597"],"award-info":[{"award-number":["16-597"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Manatu Hauora | Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["16-597"],"award-info":[{"award-number":["16-597"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Manatu Hauora | Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["16-597"],"award-info":[{"award-number":["16-597"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Manatu Hauora | Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["16-597"],"award-info":[{"award-number":["16-597"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Manatu Hauora | Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["16-597"],"award-info":[{"award-number":["16-597"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Otago, Dunedin, New Zealand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is the most common neurodegenerative disorder, yet effective preventive or therapeutic strategies remain limited. A hallmark of AD pathology is the accumulation of insoluble amyloid-\u03b2 (A\u03b2) aggregates, which are targeted by recent antibody-based therapies. Conversely, soluble amyloid precursor protein-alpha (sAPP\u03b1), a non-amyloidogenic cleavage product of APP, possesses neuroprotective, neurotrophic, and synaptogenic properties, and the ability to enhance memory. This study evaluated the therapeutic efficacy of adeno-associated virus variant PHP.eB (AAV-PHP.eB) encoding human sAPP\u03b1 in the APPswe\/PS1dE9 transgenic mouse model of AD. Six-month-old female wild-type and transgenic mice received a single intravenous injection via the tail vein. Three months post-injection, brain tissue was harvested for electrophysiological and histological analyses. The treatment significantly increased cortical sAPP\u03b1 levels and fully restored hippocampal long-term potentiation (LTP) in transgenic mice. Post-mortem analyses revealed a substantial reduction in amyloid plaque burden in both the hippocampus and cortex, with minimal plaque progression from the time of injection. However, no significant changes were observed in astrocytic (GFAP) or microglial (Iba-1) coverage, nor in soluble and insoluble A\u03b21-40 or A\u03b21-42 levels. These findings suggest that systemic AAV-PHP.eB-mediated sAPP\u03b1 delivery can ameliorate synaptic dysfunction and aggregated amyloid pathology in AD, highlighting its potential as a therapeutic strategy.<\/jats:p>","DOI":"10.1038\/s41434-026-00602-8","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:24:43Z","timestamp":1772551483000},"page":"474-485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virus-mediated gene transfer of soluble amyloid precursor protein-alpha via systemic injection in a mouse model of Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"33","author":[{"given":"Yuanyuan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce G.","family":"Mockett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Schoderboeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstin O.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi","family":"Sateesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen D.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7142-0040","authenticated-orcid":false,"given":"Stephanie M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9919-0622","authenticated-orcid":false,"given":"Wickliffe C.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"602_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173554","volume":"887","author":"M Vaz","year":"2020","unstructured":"Vaz M, Silvestre S. Alzheimer\u2019s disease: recent treatment strategies. Eur J Pharmacol. 2020;887:173554.","journal-title":"Eur J Pharmacol"},{"key":"602_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fnmol.2017.00030","volume":"10","author":"BG Mockett","year":"2017","unstructured":"Mockett BG, Richter M, Abraham WC, M\u00fcller UC. Therapeutic potential of secreted amyloid precursor protein APPs\u03b1. Front Mol Neurosci. 2017;10:30.","journal-title":"Front Mol Neurosci"},{"key":"602_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S1474-4422(19)30202-9","volume":"18","author":"D Selkoe","year":"2019","unstructured":"Selkoe D. \u03b2-secretase inhibitors for Alzheimer\u2019s disease: heading in the wrong direction? Lancet Neurol. 2019;18:624\u2013626.","journal-title":"Lancet Neurol"},{"key":"602_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","volume":"38","author":"J Cummings","year":"2024","unstructured":"Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s disease. BioDrugs. 2024;38:5\u201322.","journal-title":"BioDrugs"},{"key":"602_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-019-0447-2","volume":"12","author":"C Tackenberg","year":"2019","unstructured":"Tackenberg C, Nitsch RM. The secreted APP ectodomain, sAPP\u03b1, but not sAPP\u03b2, protects neurons against A\u03b2 oligomer-induced dendritic spine loss and increased tau phosphorylation. Mol Brain. 2019;12:27.","journal-title":"Mol Brain"},{"key":"602_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1781","volume":"3","author":"D Obregon","year":"2012","unstructured":"Obregon D, Hou H, Deng J, Giunta B, Tian J, Darlington D, et al. Soluble amyloid precursor protein-\u03b1 modulates \u03b2-secretase activity and amyloid-\u03b2 generation. Nat Commun. 2012;3:777.","journal-title":"Nat Commun"},{"key":"602_CR7","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201798335","volume":"37","author":"MC Richter","year":"2018","unstructured":"Richter MC, Ludewig S, Winschel A, Abel T, Bold C, Salzburger LR, et al. Distinct in vivo roles of secreted APP ectodomain variants APPs\u03b1 and APPs\u03b2 in regulation of spine density, synaptic plasticity, and cognition. EMBO J. 2018;37:e98335.","journal-title":"EMBO J"},{"key":"602_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00401-015-1498-9","volume":"131","author":"R Fol","year":"2016","unstructured":"Fol R, Braudeau J, Ludewig S, Abel T, Weyer SW, Roederer J-P, et al. Viral gene transfer of APPs\u03b1 rescues synaptic failure in an Alzheimer\u2019s disease mouse model. Acta Neuropathol. 2016;131:247\u2013266.","journal-title":"Acta Neuropathol"},{"key":"602_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-018-0348-9","volume":"11","author":"VTY Tan","year":"2018","unstructured":"Tan VTY, Mockett BG, Ohline SM, Parfitt KD, Wicky HE, Peppercorn K, et al. Lentivirus-mediated expression of human secreted amyloid precursor protein-alpha prevents development of memory and plasticity deficits in a mouse model of Alzheimer\u2019s disease. Mol Brain. 2018;11:7.","journal-title":"Mol Brain"},{"key":"602_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-021-00889-1","volume":"15","author":"SM Ohline","year":"2022","unstructured":"Ohline SM, Chan C, Schoderboeck L, Wicky HE, Tate WP, Hughes SM, et al. Effect of soluble amyloid precursor protein-alpha on adult hippocampal neurogenesis in a mouse model of Alzheimer\u2019s disease. Mol Brain. 2022;15:5.","journal-title":"Mol Brain"},{"key":"602_CR11","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","volume":"25","author":"JR Chamberlain","year":"2017","unstructured":"Chamberlain JR, Chamberlain JS. Progress toward gene therapy for Duchenne muscular dystrophy. Mol Ther. 2017;25:1125\u20131131.","journal-title":"Mol Ther"},{"key":"602_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu W-L, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20:1172\u20131179.","journal-title":"Nat Neurosci"},{"key":"602_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.omtm.2020.10.011","volume":"19","author":"SN Mathiesen","year":"2020","unstructured":"Mathiesen SN, Lock JL, Schoderboeck L, Abraham WC, Hughes SM. CNS transduction benefits of AAV-PHP.eB over AAV9 are dependent on administration route and mouse strain. Mol Ther Methods Clin Dev. 2020;19:447\u2013458.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"602_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0378-1119(89)90209-6","volume":"79","author":"J Miyazaki","year":"1989","unstructured":"Miyazaki J, Takaki S, Araki K, Tashiro F, Tominaga A, Takatsu K, et al. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene. 1989;79:269\u2013277.","journal-title":"Gene"},{"key":"602_CR15","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.1787","volume":"6","author":"BT Casali","year":"2016","unstructured":"Casali BT, Landreth GE. A\u03b2 extraction from murine brain homogenates. Bio Protoc. 2016;6:e1787.","journal-title":"Bio Protoc"},{"key":"602_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/sj.npp.1301559","volume":"33","author":"A Citri","year":"2008","unstructured":"Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology. 2008;33:18\u201341.","journal-title":"Neuropsychopharmacology"},{"key":"602_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/jnc.12728","volume":"130","author":"Y Kuwabara","year":"2014","unstructured":"Kuwabara Y, Ishizeki M, Watamura N, Toba J, Yoshii A, Inoue T, et al. Impairments of long-term depression induction and motor coordination precede A\u03b2 accumulation in the cerebellum of APPswe\/PS1dE9 double transgenic mice. J Neurochem. 2014;130:432\u2013443.","journal-title":"J Neurochem"},{"key":"602_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.nbd.2008.04.011","volume":"31","author":"CJ Taylor","year":"2008","unstructured":"Taylor CJ, Ireland DR, Ballagh I, Bourne K, Marechal NM, Turner PR, et al. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol Dis. 2008;31:250\u2013260.","journal-title":"Neurobiol Dis"},{"key":"602_CR19","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1523\/JNEUROSCI.1826-18.2019","volume":"39","author":"BG Mockett","year":"2019","unstructured":"Mockett BG, Gu\u00e9vremont D, Elder MK, Parfitt KD, Peppercorn K, Morrissey J, et al. Glutamate receptor trafficking and protein synthesis mediate the facilitation of LTP by secreted amyloid precursor protein-alpha. J Neurosci. 2019;39:3188\u20133203.","journal-title":"J Neurosci"},{"key":"602_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107670","volume":"157","author":"JA Morrissey","year":"2019","unstructured":"Morrissey JA, Mockett BG, Singh A, Kweon D, Ohline SM, Tate WP, et al. A C-terminal peptide from secreted amyloid precursor protein-\u03b1 enhances long-term potentiation in rats and a transgenic mouse model of Alzheimer\u2019s disease. Neuropharmacology. 2019;157:107670.","journal-title":"Neuropharmacology"},{"key":"602_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03940-3","volume":"9","author":"D Lanjakornsiripan","year":"2018","unstructured":"Lanjakornsiripan D, Pior B-J, Kawaguchi D, Furutachi S, Tahara T, Katsuyama Y, et al. Layer-specific morphological and molecular differences in neocortical astrocytes and their dependence on neuronal layers. Nat Commun. 2018;9:1623.","journal-title":"Nat Commun"},{"key":"602_CR22","first-page":"1","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9:1\u201335.","journal-title":"Signal Transduct Target Ther"},{"key":"602_CR23","doi-asserted-by":"publisher","first-page":"ENEURO.0319-23.","DOI":"10.1523\/ENEURO.0319-23.2024","volume":"11","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Kepp KP, Herrup K. Lecanemab and donanemab as therapies for Alzheimer\u2019s disease: an illustrated perspective on the data. eNeuro. 2024;11:ENEURO.0319-23.2024.","journal-title":"eNeuro"},{"key":"602_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/sj.gt.3301905","volume":"10","author":"S K\u00fcgler","year":"2003","unstructured":"K\u00fcgler S, Kilic E, B\u00e4hr M. Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther. 2003;10:337\u2013347.","journal-title":"Gene Ther"},{"key":"602_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.685802","volume":"12","author":"DJ Finneran","year":"2021","unstructured":"Finneran DJ, Njoku IP, Flores-Pazarin D, Ranabothu MR, Nash KR, Morgan D, et al. Toward the development of neuron-specific transduction after systemic delivery of viral vectors. Front Neurol. 2021;12:685802.","journal-title":"Front Neurol"},{"key":"602_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnmol.2015.00014","volume":"8","author":"LC Parr-Brownlie","year":"2015","unstructured":"Parr-Brownlie LC, Bosch-Bouju C, Schoderboeck L, Sizemore RJ, Abraham WC, Hughes SM. Lentiviral vectors as tools to understand central nervous system biology in mammalian model organisms. Front Mol Neurosci. 2015;8:14.","journal-title":"Front Mol Neurosci"},{"key":"602_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5607\/en.2016.25.1.48","volume":"25","author":"H An","year":"2016","unstructured":"An H, Cho D-W, Lee SE, Yang Y-S, Han S-C, Lee CJ. Differential cellular tropism of lentivirus and adeno-associated virus in the brain of the cynomolgus monkey. Exp Neurobiol. 2016;25:48\u201354.","journal-title":"Exp Neurobiol"},{"key":"602_CR28","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-0716-0592-9_19","volume":"2144","author":"A Christensen","year":"2020","unstructured":"Christensen A, Pike CJ. Staining and quantification of \u03b2-amyloid pathology in transgenic mouse models of Alzheimer\u2019s disease. Methods Mol Biol. 2020;2144:211\u2013221.","journal-title":"Methods Mol Biol"},{"key":"602_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3389\/fnins.2019.00735","volume":"13","author":"J Jackson","year":"2019","unstructured":"Jackson J, Jambrina E, Li J, Marston H, Menzies F, Phillips K, et al. Targeting the synapse in Alzheimer\u2019s disease. Front Neurosci. 2019;13:735.","journal-title":"Front Neurosci"},{"key":"602_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1750-1326-4-48","volume":"4","author":"GM Shankar","year":"2009","unstructured":"Shankar GM, Walsh DM. Alzheimer\u2019s disease: synaptic dysfunction and abeta. Mol Neurodegener. 2009;4:48.","journal-title":"Mol Neurodegener"},{"key":"602_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/ana.20101","volume":"55","author":"F Trinchese","year":"2004","unstructured":"Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP\/PS1 mice. Ann Neurol. 2004;55:801\u2013814.","journal-title":"Ann Neurol"},{"key":"602_CR32","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.neurobiolaging.2008.08.005","volume":"31","author":"A Volianskis","year":"2010","unstructured":"Volianskis A, K\u00f8stner R, M\u00f8lgaard M, Hass S, Jensen MS. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe\/PS1\u0394E9-deleted transgenic mice model of \u03b2-amyloidosis. Neurobiol Aging. 2010;31:1173\u20131187.","journal-title":"Neurobiol Aging"},{"key":"602_CR33","doi-asserted-by":"publisher","first-page":"9083","DOI":"10.1523\/JNEUROSCI.1492-19.2019","volume":"39","author":"A Singh","year":"2019","unstructured":"Singh A, Jones OD, Mockett BG, Ohline SM, Abraham WC. Tumor necrosis factor-\u03b1-mediated metaplastic inhibition of LTP is constitutively engaged in an Alzheimer\u2019s disease model. J Neurosci. 2019;39:9083\u20139097.","journal-title":"J Neurosci"},{"key":"602_CR34","doi-asserted-by":"publisher","first-page":"7817","DOI":"10.1523\/JNEUROSCI.1026-07.2007","volume":"27","author":"S Ring","year":"2007","unstructured":"Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, et al. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci. 2007;27:7817\u20137826.","journal-title":"J Neurosci"},{"key":"602_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neulet.2009.05.040","volume":"460","author":"AM Claasen","year":"2009","unstructured":"Claasen AM, Gu\u00e9vremont D, Mason-Parker SE, Bourne K, Tate WP, Abraham WC, et al. Secreted amyloid precursor protein-alpha upregulates synaptic protein synthesis by a protein kinase G-dependent mechanism. Neurosci Lett. 2009;460:92\u201396.","journal-title":"Neurosci Lett"},{"key":"602_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcdb.2022.05.014","volume":"139","author":"BG Mockett","year":"2023","unstructured":"Mockett BG, Ryan MM. The therapeutic potential of the neuroactive peptides of soluble amyloid precursor protein-alpha in Alzheimer\u2019s disease and related neurological disorders. Semin Cell Dev Biol. 2023;139:93\u2013101.","journal-title":"Semin Cell Dev Biol"},{"key":"602_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jalz.2014.01.007","volume":"11","author":"P Bradley","year":"2015","unstructured":"Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, et al. Taking stock: a multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer\u2019s disease. Alzheimer's Dement. 2015;11:455\u2013461.","journal-title":"Alzheimer's Dement"},{"key":"602_CR38","doi-asserted-by":"publisher","first-page":"15079","DOI":"10.1021\/acs.iecr.9b02196","volume":"58","author":"ME Wechsler","year":"2019","unstructured":"Wechsler ME, Ramirez JEV, Peppas NA. 110th Anniversary: nanoparticle-mediated drug delivery for the treatment of Alzheimer\u2019s disease: Crossing the blood-brain barrier. Ind Eng Chem Res. 2019;58:15079\u201315087.","journal-title":"Ind Eng Chem Res"},{"key":"602_CR39","doi-asserted-by":"publisher","first-page":"e12111","DOI":"10.1002\/trc2.12111","volume":"7","author":"A Waters","year":"2021","unstructured":"Waters A, Laitner MHSociety for Women\u2019s Health Research Alzheimer\u2019s Disease Network. Biological sex differences in alzheimer\u2019s preclinical research: a call to action. Alzheimer's Dement. 2021;7:e12111.","journal-title":"Alzheimer's Dement"},{"key":"602_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/JAD-201014","volume":"80","author":"JL Dennison","year":"2021","unstructured":"Dennison JL, Ricciardi NR, Lohse I, Volmar C-H, Wahlestedt C. Sexual dimorphism in the 3xTg-AD mouse model and its impact on pre-clinical research. J Alzheimers Dis. 2021;80:41\u201352.","journal-title":"J Alzheimers Dis"},{"key":"602_CR41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.nbd.2003.08.009","volume":"14","author":"J Wang","year":"2003","unstructured":"Wang J, Tanila H, Puoliv\u00e4li J, Kadish I, Groen Tvan. Gender differences in the amount and deposition of amyloid\u03b2 in APPswe and PS1 double transgenic mice. Neurobiol Dis. 2003;14:318\u2013327.","journal-title":"Neurobiol Dis"},{"key":"602_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neulet.2017.11.049","volume":"665","author":"Y Matsuzaki","year":"2018","unstructured":"Matsuzaki Y, Konno A, Mochizuki R, Shinohara Y, Nitta K, Okada Y, et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci Lett. 2018;665:82\u2013188.","journal-title":"Neurosci Lett"},{"key":"602_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","volume":"25","author":"D Goertsen","year":"2022","unstructured":"Goertsen D, Flytzanis NC, Goeden N, Chuapoco MR, Cummins A, Chen Y, et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat Neurosci. 2022;25:106\u2013115.","journal-title":"Nat Neurosci"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00602-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:57:11Z","timestamp":1786607831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00602-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00602-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7615037\/v1","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal use was compliant with New Zealand\u2019s Animal Welfare Act 1991 and all procedures were approved by the University of Otago Animal Ethics Committee (approval #19\/90).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}